Condition: Immunotherapy Esophagus Cancer · Sponsor: Fuzhou General Hospital
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)
This description comes directly from the study's public registry record.
Fu zhi chao, Doctor of Medicine · 13774562945 · fauster1112@126.com
Always discuss trial participation with your own doctor first.
| Ye zai sheng | Fuzhou, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05515315